Peptide Grading
Research peptide
Tesamorelin
From
$22.99
Vendors
22
Lab tested
5 COAs
Key benefits
- About 15% less belly fat in trials
- Reduces liver fat in HIV
- Boosts natural GH pulses
- Improved body image in trials
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing factor (GRF). The peptide carries an N-terminal hexenoyl group, a structural change that distinguishes it from native GRF while retaining activity at the GRF receptor.
Tesamorelin has been studied extensively in human endocrine research, particularly in work involving growth hormone release and IGF-1 response. Peptide Grading compares current listings by supplier, quantity, stated specifications, COA availability, shipping, and price per mg.
Typical dose
1.4-2 mg Once daily
Route
Subcutaneous
Administer once daily, typically in the morning or before bed.
Cycle
Continuous Typical duration
Storage
Powder: 2-8°C | Reconstituted: 20-25°C Refrigerated
Follow vendor guidance
Marketplace
Compare all Tesamorelin vendors
Prices per size, coupon codes, lab reports and shipping.
| Vendor | Price | Coupon | Lab test | Shipping | |
|---|---|---|---|---|---|
Certa Peptides 2 mg | $22.99 Lowest price$11.49/mg | Not on file | 1–4 days
| Buy | |
Reta One Labs 10 mg | $39.00 $3.90/mg | Not on file | 2 days
| Buy | |
 PepVida Labs 10 mg | $43.73$55.00 −20.5%$4.37/mg | Not on file | 1-3 days
| Buy | |
Biologix Labs 5 mg | $43.99$54.99 −20%$8.80/mg | Not on file | 2 Days
| Buy | |
HLX LABS 5 mg | $44.99$74.99 −40%$9.00/mg | Not on file | 2–5 days
| Buy | |
Renova Peptides 10 mg | $49.00 $4.90/mg | No code | Not on file | 3–5 days
| Buy |
Trulab Peptides 2 mg | $49.00 $24.50/mg | Not on file | 2–5 days
| Buy | |
idunpeptides 10 mg | $49.99 $5.00/mg | Not on file | 3–7 days
| Buy |
Switzerland, United Kingdom +29
United States- No codeBuy
What is Tesamorelin?
Tesamorelin
Compound
Tesamorelin
Tesamorelin Structure
Tesamorelin retains the 44-amino-acid human GRF sequence with a hexenoyl group attached to the N-terminal tyrosine. FDA pharmacology data found greater resistance to enzymatic degradation in human serum, while receptor binding remained comparable with native GRF.
What Clinical Studies Measured
The main human studies were conducted in people with HIV-associated lipodystrophy. Their primary endpoint was visceral adipose tissue (VAT), measured by CT rather than body weight alone. IGF-1 and other metabolic measures were assessed alongside VAT.
In a 26-week trial of 412 participants, VAT decreased by 15.2% with Tesamorelin, compared with a 5.0% increase with placebo.
Tesamorelin vs Sermorelin
| Compound | Main structural feature | Length | Key distinction |
|---|---|---|---|
| Basis | GRF(1-44) | GHRH(1-29) | |
| Design | Modified full-length GRF | Short GHRH fragment | |
| Key modification | N-terminal hexenoyl | C-terminal amidation | |
| Major clinical focus | HIV-associated lipodystrophy | GH-related research |
VAT vs Other Fat Depots
The effect was mainly seen in visceral fat. Studies did not show the same reduction in abdominal subcutaneous fat. Research also reported changes in liver fat alongside the reduction in VAT.
The VAT reduction depended on continued treatment. Participants who stopped Tesamorelin and switched to placebo showed reaccumulation of visceral fat during follow-up.
## Clinical Development
Tesamorelin was developed specifically around excess visceral abdominal fat associated with HIV lipodystrophy. Its FDA-approved indication is limited to that setting and does not represent a general weight-management indication.
## FDA Regulatory History
Tesamorelin received FDA approval for its specific pharmaceutical indication, with later formulations including EGRIFTA SV and EGRIFTA WR.
This approval applies to defined pharmaceutical formulations and should not automatically be extended to unrelated research-grade Tesamorelin materials.
Safety and Regulatory Context
Clinical studies have identified issues including IGF-1 elevation, glucose-related effects, hypersensitivity, and anti-tesamorelin antibodies. Current research materials should be assessed separately from FDA-approved formulations.
Tesamorelin and WADA
Tesamorelin is prohibited under WADA S2.2.4 as a growth hormone-releasing factor.
Research reference note
Research Use Disclaimer
[Peptide Grading](#vendor-listings) helps researchers compare Tesamorelin listings, supplier specifications, [COAs](/coas), quantities, shipping details, and price-per-mg data.
FAQ
Frequently asked questions.
VAT directly measures visceral abdominal fat, the main tissue compartment studied during Tesamorelin's clinical development.